Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats : impact of oxidative stress, inflammation and apoptosis
Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Toxicology mechanisms and methods - 26(2016), 5 vom: 06. Juni, Seite 371-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kelleni, Mina T [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.03.2017 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15376516.2016.1191576 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM261119508 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM261119508 | ||
| 003 | DE-627 | ||
| 005 | 20231224194852.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15376516.2016.1191576 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0870.xml |
| 035 | |a (DE-627)NLM261119508 | ||
| 035 | |a (NLM)27269004 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kelleni, Mina T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats |b impact of oxidative stress, inflammation and apoptosis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2017 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Methotrexate (MTX) is a commonly used antineoplastic and anti-rheumatoid drug whose efficacy is limited by its hepatotoxicity. The aim of this study was to investigate the possible protective role of captopril (100 mg/kg/day, p.o. for seven days), an angiotensin converting enzyme inhibitor, and telmisartan (10 mg/kg/day p.o. for seven days), an angiotensin II receptor blocker with peroxisome proliferative receptor gamma (PPARγ) agonism, in a model of MTX (single dose 20 mg/kg i.p. at the fifth day) induced hepatotoxicity in rats. Results of the present study revealed MTX-induced hepatotoxicity as demonstrated by increased level of liver enzymes and confirmed by histopathology. Pretreatment with captopril or telmisartan produced a significant hepatic protection manifested as a significant (p < 0.05) decrease in serum levels of alanine transferase (ALT) and aspartate transferase (AST) and alkaline phosphatase (ALP) enzymes; hepatic malondialdehyde (MDA) and total nitrites and nitrates (NOx) levels; as well as a significant increase in hepatic superoxide dismutase (SOD) activity. In addition, there was a remarkable improvement in the histopathological features and a significant reduction in the expression of COX-2, iNOS and caspase-3 enzymes as compared with the MTX group. We recommend considering captopril/Telmisartan, if tolerated and not contraindicated, as preferable antihypertensive agents in patients receiving MTX in their chemotherapy protocols | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Captopril | |
| 650 | 4 | |a hepatotoxicity | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a telmisartan | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Benzoates |2 NLM | |
| 650 | 7 | |a Protective Agents |2 NLM | |
| 650 | 7 | |a Captopril |2 NLM | |
| 650 | 7 | |a 9G64RSX1XD |2 NLM | |
| 650 | 7 | |a Nitric Oxide Synthase Type II |2 NLM | |
| 650 | 7 | |a EC 1.14.13.39 |2 NLM | |
| 650 | 7 | |a Nos2 protein, rat |2 NLM | |
| 650 | 7 | |a EC 1.14.13.39 |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 650 | 7 | |a Ptgs2 protein, rat |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 650 | 7 | |a Telmisartan |2 NLM | |
| 650 | 7 | |a U5SYW473RQ |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Ibrahim, Salwa A |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrahman, Aly M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Toxicology mechanisms and methods |d 2002 |g 26(2016), 5 vom: 06. Juni, Seite 371-7 |w (DE-627)NLM190823402 |x 1537-6524 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2016 |g number:5 |g day:06 |g month:06 |g pages:371-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15376516.2016.1191576 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2016 |e 5 |b 06 |c 06 |h 371-7 | ||